ClinicalTrials.gg
CompletedNCT01500408Updated Nov 19, 2012

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

A Phase 1 interventional study of Interferon beta-1a (current approved manufacturing process invloving FBS) and Interferon beta-1a (new process, manufactured without FBS) in Multiple Sclerosis, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-19.

Sponsored by Biogen · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.

Enrollment
13th of 34
110 · median 85
Started
2012
with 1 other
Phase 1
4 of 34
none open now
Registered
27th of 34
by date
Lead sponsor
15 of 34
Biogen

Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 13th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 1, and was the 27th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing Interferon beta-1a in Multiple Sclerosis as a file.
02

Study summary

Biogen Idec has developed a novel process to manufacture Interferon beta-1a (INFB), the active ingredient of Avonex®, that does not include fetal bovine serum (FBS). This bioequivalence study is being conducted to confirm the pharmacokinetic (PK) and pharmacodynamic (PD) comparability of Interferon beta-1a produced by the currently approved serum-containing process and Interferon beta-1a produced by the new serum-free manufacturing process.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the purpose and risks of the study and provide signed and dated and authoriziation to use protected health information (PHI) in accordance with national and local subject privacy regulations.
  2. Must be healthy males or females 18 to 45 years old, inclusive, at the time of informed consent.
  3. Must have a (BMI) of 18.5 to 30.0 kg/ m2, inclusive, and a minimum body weight of 50.0 kg at Screening and Day-1 Baseline.
  4. Subjects of must practice effective during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Known history of (HIV).
  2. Positive test result at Screening for antibody (HCV Ab) or current infection (defined as positive for hepatitis surface antigen [HBcAb] at Screening). Subjects with immunity to hepatitis B from either active vaccination (defined as negative HBsAg, positive hepatitis B surface anitbody [HBsAg], and negative HBcAb) or from previous natural infection (defined as negative HBsAg, positive HBsAb immunoglobulin G, and positiveHBcAb) are eligible to participate in the study (definitions are based on the Centers for Disease Control and Prevention interpretation of the hepatitis B serology panel).
  3. Subjects with a history of malignant disease, including solid tumors and hematologic (except basal cell and squamos cell carcinomas of the skin that have been completely excised and are considered cured).
  4. History of severe allergic or anaphylactic reactions.
  5. Known allergy to any component of the IFN B-1a formulation, including a dry rubber allergy.
  6. History of any cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
  7. History of seizure disorder or unexplained blackouts.
  8. History of suicidal ideation or an episode of clinically severe depression (as determined by the Investigator).
  9. Serious local infection (e.g., cellulitis, abscess) or systemic infection (pneumonia, septicemia), at the discretion of the Investigator, within 3 months prior to Day 1.
  10. History of drug or alcohol abuse (as defined by the Investigator) within 6 months prior to Screening.
  11. Positive testing for drugs and alcohol at Screening or baseline (Day-1).
  12. Alcohol use within 48 hours prior to Day 1. Subjects must be willing to restrict alcohol use throughout their participation in the study. Subjects may not consume more than 1 alcoholic beverage per day during this study where 1 alcoholic beverage is defined as ≤8 ounces of beer or ≤4 ounces of wine.
  13. Fever (body temperature >38°C) or symptomatic viral or bacterial infection (including upper respiratory infection) within 1 week prior to Day 1.
  14. Clinically significant abnormal clinical laboratory test values, as determined by the Investigator, or any values for (ALT), aspartate aminotransferase (AST), or creatinine that are above the , any values for or that are below the lower limit of normal, or any out of normal range values for white blood cells, serum sodium, or serum potassium.
  15. Any previous treatment with any interferon product, including use.
  16. History of or intolerance to acetaminophen (paracetamol), ibuprofen, naproxen, or aspirin that would preclude use of at least 1 of these during the study.
  17. Prior treatment with any investigational drug within the 30 days prior to Day 1, or within 5 half-lives of the drug, whichever is longer.
  18. Treatment with any medication including over-the-counter (OTC) products within 48 hours prior to Day 1, except for the following treatments, which are allowed: , hormone replacement therapy (HRT), local, non-systemically absorbed (i.e., topical, nasal/inhaled), acetaminophen (paracetamol), ibuprofen, naproxen, and/or aspirin.
  19. Female subjects who are pregnant or currently breastfeeding or have a positive pregnancy test result.
  20. Vaccinations within 4 weeks prior to Day 1.
  21. Blood donation (1 unit or more) within 1 month prior to Day 1.
  22. Current enrollment in any other study treatment or disease study.
  23. Inability to comply with study requirements.
  24. Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the subject unsuitable for enrollment.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
110 participants (actual)

Study arms

  • Other
    Commercial INFB followed by Investigational INFB

    Process A (currently-approved manufacturing process involving FBS) first, then Process B (new serum-free manufacturing process, without FBS)

    Drug: Interferon beta-1a (current approved manufacturing process invloving FBS) · Drug: Interferon beta-1a (new process, manufactured without FBS)

  • Other
    Investigational INFB followed by Commercial INFB

    Process B (new serum-free manufacturing process, without FBS) first, then Process A (currently-approved manufacturing process involving FBS)

    Drug: Interferon beta-1a (current approved manufacturing process invloving FBS) · Drug: Interferon beta-1a (new process, manufactured without FBS)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve (AUC) as a measure of PK.

    Time frame: Subjects will be followed for the duration of the study, 22 days. PK samples will be taken 5 to 60 minutes prior to dosing, and post dose at hours 2, 4, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, 72, 96 and 168.

Secondary outcomes

  1. The observed maximum (peak) serum Interferon beta-1a concentration (Cmax)

    Time frame: Subjects will be followed for the duration of the study, 22 days. PK samples will be taken 5 to 60 minutes prior to dosing, and post dose at hours 2, 4, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, 72, 96 and 168.

07

Study locations

1 site
  • Research Site
    St. Paul, Minnesota, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2011
First posted
Dec 28, 2011
Start
Jan 2012
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Last update
Nov 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01500408
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Dec 28, 2011
Start date
Jan 2012
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Nov 19, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion